Loading stock data…
MMED
$11.21-0.36 (-3.11%)
Market OpenUpdated 3:49 PM EDT
Minimed Group, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$11.21
Potential Upside
5%
Whystock Fair Value$11.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$22.45+100.3%
Range$16.00 – $27.00
Fundamentals
Minimed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pe...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.08%
Volume
Today's trading volume
476,598
Recent News
Is It Time To Reassess MiniMed Group (MMED) After This Year’s Sharp Share Price Fall
Wondering whether MiniMed Group at around US$11.57 is starting to look like value or still has more downside risk? This article breaks down what the current price might be implying. The stock has been under pressure recently, with the share price down 2.5% over the past week, 16.9% over the past month, and 37.4% year to date. This can change how the market views both risk and potential reward. Recent news coverage has largely focused on MiniMed Group's position within the medical equipment...
Why Savvy Investors Are Loading Up on This Beaten-Down Stock
Medtronic is closing in on Dividend King status, and its surgical robot is gaining traction.
UBS and Jefferies Lower Views on Medtronic (MDT) Amid Diabetes Unit Changes
With an annual dividend yield of 3.41%, Medtronic plc (NYSE:MDT) is included among the 10 Best High-Yield Dividend Growth Stocks to Buy Right Now. On April 22, UBS lowered the firm’s price recommendation on Medtronic plc (NYSE:MDT) to $90 from $104. It reiterated a Neutral rating on the shares. The firm updated its model to reflect […]
Is It Time To Revisit Minimed Group (MMED) After Recent Share Price Weakness?
Wondering if Minimed Group at around US$14.01 is pricing in too much hope or not enough? This article walks through the numbers so you can judge the value story for yourself. The stock has seen a 3.2% decline over the last 7 days and a 24.2% decline year to date, which can change how the market views both its potential and its risks. Recent coverage of Minimed Group has focused on its position within the healthcare sector and how sentiment around medical equipment names has shifted. This...
Goldman Sachs Says Markets Stay Strong – Picks 2 ‘Strong Buy’ Stocks to Consider
The US-led campaign against Iran is now about a month old, and while markets have been volatile, they’re holding up better than many expected. Stocks initially sold off as oil prices surged and inflation fears picked up, but the broader pullback has been relatively contained, with declines measured in the mid-single digits rather than anything more severe. At Goldman Sachs, asset allocation head Christian Mueller-Glissmann points to a few key forces helping keep that stability in place. Last yea